Slide 1: First Quarter 2026 Financial Results & Business Update
First Quarter 2026 Financial Results & Business Update May 5, 2026
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm
Slide 3: Q1 2026 Financial and Operational Performance
Q1 2026 Financial and Operational Performance
Slide 4: Q1 2026 Financial Results Summary
Q1 2026 Financial Results Summary Total Revenue GAAP Net Income/(Loss) GAAP Earnings (Loss) Per Share Diluted In millions In millions $392.9 $22.5 $306.5 $0.13 ($0.40) ($66.5) Q1 2025 Q1 2026 Q1 2025 Q1 2026 Q1 2025 Q1 2026 2026 results reflect the acquisition of Avadel in February 2026, including s
Slide 5: Q1 2026 Profitability
Q1 2026 Profitability GAAP Net Income/(Loss) EBITDA* Adjusted EBITDA* In millions In millions In millions $22.5 $22.8 $80.3 $45.6 ($30.1) ($66.5) Q1 2025 Q1 2026 Q1 2025 Q1 2026 Q1 2025 Q1 2026 EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes s
Slide 6: Q1 2026 Revenue Summary
Q1 2026 Revenue Summary In millions Q1’26 Q1’25 Total Proprietary Net Sales $338.1 $244.5 VIVITROL® $112.4 $101.0 ARISTADA®* $93.8 $73.5 LYBALVI® $92.4 $70.0 LUMRYZ® $39.5 ** - Manufacturing & Royalty Revenue $54.8 $62.0 Total Revenue $392.9 $306.5 Amounts in the table may not sum due to rounding. *
Slide 7: Alkermes: 2026 Financial Expectations
Alkermes: 2026 Financial Expectations* Previous Financial Updated Financial Expectations for Year Ending Expectations for Year Ending (in millions) Dec. 31, 2026 Dec. 31, 2026* (provided Feb. 25, 2026) (provided May 5, 2026) Total Revenues $1,730 – $1,840 $1,730 – $1,840 Expected net sales of propri
Slide 8: Q1 2026 Commercial Review
Q1 2026 Commercial Review
Slide 9: VIVITROL Performance and Expectations
VIVITROL® Performance and Expectations VIVITROL Quarterly Net Sales ($M) $140 Q1’26 VIVITROL net sales were $112.4M $120 Outlook: • FY’26 net sales expected to range from $100 $460M – $480M* $80 $60 $40 $20 $0 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 *These expectations were initially p
Slide 10: ARISTADA Performance and Expectations
ARISTADA® Performance and Expectations ARISTADA Quarterly Net Sales* ($M) Q1’26 ARISTADA net sales were $93.8M $100 Outlook: • FY’26 net sales expected to range from $80 $365M – $385M†* $60 $40 $20 $0 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 *Inclusive of ARISTADA INITIO® †These expecta
Slide 11: LYBALVI Performance and Expectations
LYBALVI® Performance and Expectations LYBALVI Quarterly Net Sales ($M) $100 Q1’26 LYBALVI net sales of $92.4M • Q1’26 gross-to-net deductions: ~33% $80 Outlook: • FY’26 net sales expected to range from $60 $380M – $400M* $40 $20 $0 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 *These expecta
Slide 12: LUMRYZ Performance and Expectations
LUMRYZ® Performance and Expectations LUMRYZ Quarterly Net Sales ($M) Q1’26 LUMRYZ net sales recorded by Alkermes Avadel Alkermes were $39.5M $100 • Prior to the completion of the acquisition, $80 Avadel recorded LUMRYZ net sales of ~$33M between Jan. 1, 2026 and $60 Feb. 11, 2026 Outlook: $40 • FY’2
Slide 13: Appendix
Appendix
Slide 14: Appendix: Financial Results GAAP to Non-GAAP Reconciliation
Appendix: Financial Results GAAP to Non-GAAP Reconciliation Three Months Ended Three Months Ended (In millions) March 31, 2026 March 31, 2025 Net (Loss) Income — GAAP $ (66.5) $ 22.5 Adjustments: Depreciation expense 7.8 7.4 Amortization expense 11.7 - Interest income (8.5) (10.1) Interest expense 2
Slide 15: Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation
Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation Year Ending (In millions) December 31, 2026 Projected Net Loss — GAAP $ (80.0) Adjustments: Net interest expense 80.0 Depreciation and amortization expense 120.0 Income tax benefit -- Projected EBTIDA $ 120.0 Shared-based compensation
Slide 16: www.alkermes.com
www.alkermes.com © 2026 Alkermes. All rights reserved.